Background Respiratory syncytial virus (RSV) causes respiratory disease throughout life. Here we report differences in naturally acquired immunity with age and presumed exposure. Methods A longitudinal, non-interventional, observational study was performed in healthy adults (20 paediatric healthcare workers and 10 non-healthcare workers), children (10 aged 3–6 years) and infants (5 aged 2–4 months and 20 aged 6–12 months). Blood samples were analysed for RSV-neutralising antibody titre, F/Ga/Gb-specific antibody titres, F-specific IgG/IgA memory B-cell frequencies and T-cell production of IFNγ, IL-4, IL-13 and IL-17. Results Serum G-specific antibody titres were significantly lower in infants and children than adults. However, serum titres...
Since its discovery 60 years ago, we have greatly improved our knowledge of RSV disease. Many risk f...
RSV infections are ubiquitous in children but are most severe in infants in the first few months of ...
AbstractTo determine the age at which infants mount significant neutralising antibody responses to b...
Respiratory syncytial virus (RSV) is one of the most prevalent causative agents of lower respiratory...
The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitat...
The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitat...
The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitat...
Humoral immunityprotects against severe respiratory syncytial virus (RSV)disease, but the range andm...
The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitat...
We have evaluated the cellular and humoral immune response to primary respiratory syncytial virus (R...
ABSTRACT: The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be...
ABSTRACT: The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be...
ABSTRACT: The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be...
Since its discovery 60 years ago, we have greatly improved our knowledge of RSV disease. Many risk f...
Respiratory syncytial virus (RSV) represents an important target for vaccine development. The design...
Since its discovery 60 years ago, we have greatly improved our knowledge of RSV disease. Many risk f...
RSV infections are ubiquitous in children but are most severe in infants in the first few months of ...
AbstractTo determine the age at which infants mount significant neutralising antibody responses to b...
Respiratory syncytial virus (RSV) is one of the most prevalent causative agents of lower respiratory...
The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitat...
The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitat...
The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitat...
Humoral immunityprotects against severe respiratory syncytial virus (RSV)disease, but the range andm...
The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be facilitat...
We have evaluated the cellular and humoral immune response to primary respiratory syncytial virus (R...
ABSTRACT: The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be...
ABSTRACT: The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be...
ABSTRACT: The development of a safe and effective respiratory syncytial virus (RSV) vaccine might be...
Since its discovery 60 years ago, we have greatly improved our knowledge of RSV disease. Many risk f...
Respiratory syncytial virus (RSV) represents an important target for vaccine development. The design...
Since its discovery 60 years ago, we have greatly improved our knowledge of RSV disease. Many risk f...
RSV infections are ubiquitous in children but are most severe in infants in the first few months of ...
AbstractTo determine the age at which infants mount significant neutralising antibody responses to b...